BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37175524)

  • 21. [Incidence and physiopathology of high-grade dysplasia in Barrett's esophagus].
    Coriat R; Perkins G; Brezault C
    Presse Med; 2011 May; 40(5):496-501. PubMed ID: 21435817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
    Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
    Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
    Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
    Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.
    Slaby O; Srovnal J; Radova L; Gregar J; Juracek J; Luzna P; Svoboda M; Hajduch M; Ehrmann J
    Carcinogenesis; 2015 May; 36(5):521-7. PubMed ID: 25784377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus.
    Craig MP; Rajakaruna S; Paliy O; Sajjad M; Madhavan S; Reddy N; Zhang J; Bottomley M; Agrawal S; Kadakia MP
    Clin Transl Gastroenterol; 2020 Jan; 11(1):e00125. PubMed ID: 31934893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophil-Lymphocyte Ratio as a Marker of Progression from Non-Dysplastic Barrett's Esophagus to Esophageal Adenocarcinoma: a Cross-Sectional Retrospective Study.
    Campos VJ; Mazzini GS; Juchem JF; Gurski RR
    J Gastrointest Surg; 2020 Jan; 24(1):8-18. PubMed ID: 31745889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The sequential model of Barrett's esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens.
    Sato T; Miwa K; Sahara H; Segawa M; Hattori T
    Anticancer Res; 2002; 22(1A):39-44. PubMed ID: 12017320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical management of Barrett's esophagus.
    Clark GW; DeMeester TR
    Ann Chir Gynaecol; 1995; 84(2):139-44. PubMed ID: 7574371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From reflux esophagitis to Barrett's esophagus and esophageal adenocarcinoma.
    Wang RH
    World J Gastroenterol; 2015 May; 21(17):5210-9. PubMed ID: 25954094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
    Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Thrift AP
    Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Carcinogenesis of Barrett's esophagus].
    Endo T; Sugawara N; Shinomura Y
    Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cross sectional study of p504s, CD133, and Twist expression in the esophageal metaplasia dysplasia adenocarcinoma sequence.
    Ahmad J; Arthur K; Maxwell P; Kennedy A; Johnston BT; Murray L; McManus DT
    Dis Esophagus; 2015 Apr; 28(3):276-82. PubMed ID: 24612412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
    Weston AP; Badr AS; Hassanein RS
    Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
    Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
    Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for esophageal adenocarcinoma and precancerous conditions (dysplasia and Barrett's esophagus) in patients with chronic gastroesophageal reflux disease with or without other risk factors: two systematic reviews and one overview of reviews to inform a guideline of the Canadian Task Force on Preventive Health Care (CTFPHC).
    Hamel C; Ahmadzai N; Beck A; Thuku M; Skidmore B; Pussegoda K; Bjerre L; Chatterjee A; Dennis K; Ferri L; Maziak DE; Shea BJ; Hutton B; Little J; Moher D; Stevens A
    Syst Rev; 2020 Jan; 9(1):20. PubMed ID: 31996261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.